Anaplastic thyroid cancer: Prevalence, diagnosis and treatment

Minerva Endocrinologica

Volumn 33, Issue 4, 2008, Pages 341-357

  Chiacchio, S ^a   Lorenzoni, A ^a   Boni, G ^a   Rubello, D ^b   Elisei, R ^a   Mariani, G ^a  

^a UNIVERSITY OF PISA   (Italy)

^b S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Prognosis; Thyroid neoplasms, diagnosis; Thyroid neoplasms, epidemiology; Thyroid neoplasms, pathology; Thyroid neoplasms, therapeutics

Indexed keywords

BETA CATENIN; CALCITONIN; CD97 ANTIGEN; CHROMOGRANIN; CYTOKERATIN; HYALIN; INTERLEUKIN 6; INTERLEUKIN 8; KERATIN; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

ADULT; AGED; ASPIRATION BIOPSY; BLEEDING; BONE METASTASIS; BRAIN METASTASIS; CASE REPORT; CELL GROWTH; CELL INFILTRATION; CELL NUCLEUS; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; CYTOPLASM; DYSPHAGIA; DYSPHONIA; DYSPNEA; ESOPHAGUS; FEMALE; GIANT CELL; GOITER; HISTOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG METASTASIS; LYMPHOMA; MITOSIS RATE; NECK PAIN; NECROSIS; OVARY FOLLICLE CELL; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SKIN METASTASIS; SOCIOECONOMICS; SQUAMOUS CELL CARCINOMA; STRIDOR; THYROID CANCER; THYROID CARCINOMA; THYROID DISEASE; THYROID PARAFOLLICULAR CELL; TRACHEA; TUMOR SUPPRESSOR GENE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGE DISTRIBUTION; CANCER STAGING; CARCINOMA; ITALY; METHODOLOGY; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROGNOSIS; RISK FACTOR; SEX RATIO; THYROID TUMOR; THYROIDECTOMY;

AGE DISTRIBUTION; BIOPSY, FINE-NEEDLE; CARCINOMA; CHEMOTHERAPY, ADJUVANT; HUMANS; INCIDENCE; ITALY; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SEX DISTRIBUTION; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 60849091644     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. De Groot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-24. (Pubitemid 20261828)
2. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA et al. The results of various modalities of treatment of well-differentiated thyroid carcinomas: A retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-20.
3. Neff RL, Farrar WB, Kloos BT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008;37:525-738.
4. Ain KB. Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches. Thyroid 1998;8:715-26
5. Aldinger KA, Samaan NA, Ibanez M. Hill CS Jr. Anaplastic carcinoma of the thyroid: A review of 84 cases of spindle and giant-cell carcinoma of the thyroid. Cancer 1978;41:2267-75.
6. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid cancer: a study of 70 cases. Am J Clin Pathol 1983;2:135-58.
7. Rosai J, Saxen EA, Woolner L. Undifferentiated and poorly differentiated carcinoma. Semin Diagn Pathol 1985;2:123-36.
8. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-64.
9. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006;13:119-28.
10. Rossi R, Cady B, Meissner WA, Sedgwick CE, Werber J. Prognosis of undifferentiated carcinoma and lymphoma of the thyroid. Am J Surg 1978;135:589-96.
11. Nishiyama RH, Dunn EL, Thompson NW. Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer 1972;30:113-27.
12. th edition. New York: Springer-Verlag, 2002: 77.
13. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 1999;16:64-9.
14. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335-42.
15. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB et al. Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 2001;130:1028-34.
16. Chang HS, Nam KH, Chung WY, Park CS. Anaplastic thyroid carcinoma: a therapeutic dilemma. Yonsei Med J 2005;46:759-64.
17. Jiang JY, Tseng FY. Prognostic factors of anaplastic thyroid carcinoma. J Endocrinol Invest 2006;29:11-17. (Pubitemid 43355830)
18. Kim TY, Kim KW, Jung TS, Kim SW, Chung KW, Kim EY et al. Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck 2007;29:765-72.
19. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 2007;14:719-29.
20. Hadar T, Mor C, Shvero J, Levy R, Segal K. Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 1993;19:511-6.
21. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 2000;11:1083-9.
22. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998;83:2638-48.
23. Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Incidence of thyroid cancer in Norway 1970-1985. Population review on time trend, sex, age, histological type and tumour stage in 2625 cases. APMIS 1990;98:549-58.
24. Ezaki H, Ebihara S, Fujimoto Y, Iida F, Ito K, Kuma K et al. Analysis of thyroid carcinoma based on material registered in Japan during 1977-1986 with special reference to predominance of papillary type. Cancer 1992;70:808-14.
25. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
26. Cady B, Rossi RL. Undifferentiated carcinoma and lymphoma of thyroid gland. In: Cady B, Rossi RL, editors. Surgery of the thyroid and parathyroid glands. Philadelphia: WB Saunders, 1991:179-86.
27. Agrawal S, Rao RS, Parikh EM, Parikh HK, Borges AM, Sampat MB. Histologic trends in thyroid cancer 1969-93: a clinicopathologic analysis of the relative proportion of anaplastic carcinoma of the thyroid. J Surg Oncol 1996;63:251-5.
28. Lampertico P. Anaplastic (sarcomatoid) carcinoma of the thyroid gland. Semin Diagn Pathol 1993;10:159-68. (Pubitemid 23204899)
29. Tobler A, Maurer R, Hedinger CE. Undifferentiated thyroid tumors of diffuse small cell type. Histological and immunohistochemical evidence for their lymphomatous nature. Virchows Arch A Pathol Anat Histopathol 1984;404:117-26.
30. Myskow MW, Krajewski AS, Dewar AE, Millar EP, McLaren K, Fabre JW. The role of immunoperoxidase techniques on paraffin embedded tissue in determining the histogenesis of undifferentiated thyroid neoplasms. Clin Endocrinol 1986;24:335-41.
31. Holting T, Moller P, Tschahargane C, Meybier H, Buhr H, Herfarth C. Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma. World J Surg 1990;14:291-5.
32. Tan RK, Finley RK III, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP. Anaplastic carcinoma of the thyroid: a 24 year experience. Head Neck 1995;17:41-8.
33. Spires JR, Schwartz MR, Miller RH. Anaplastic thyroid carcinoma: association with differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 1988;114:40-4.
34. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer 1990;66:321-30.
35. Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991;110:956-63.
36. Bakiri F, Djemli FK, Mokrane LA, Djidel FK. The relative roles of endemic goiter and socio-economic development status in the prognosis of thyroid carcinoma. Cancer 1998;82:1146-53.
37. De May RM. The art and science of cytopathology. Chicago: ASCP Press; 1996.
38. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002;86:1848-53.
39. Ordonez NG, El Naggar AK, Hickey RC, Samaan NA. Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. Am J Clin Pathol 1991;96:15-24.
40. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92. (Pubitemid 24273002)
41. Chan JK, Banks PM, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B et al. A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol 1995;103:543-60.
42. Fagin JA. Molecular genetics of human thyroid neoplasms. Annu Rev Med 1994;45:45-52.
43. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404.
44. Lazzereschi D, Ranieri A, Mincione G, Taccogna S, Nardi F, Colletta G. Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein. Cancer Res 1997;57:2071-6.
45. Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, Lotz O et al. CD97: A dedifferentiation marker in human thyroid carcinomas. Cancer Res 1997;57:1798-806.
46. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999;59:1811-5.
47. Komoike Y, Tamaki Y, Sakita I, Tomita N, Ohue M, Sekimoto M et al. Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid carcinoma. Int J Oncol 1999;14:1157-62.
48. Fiore L, Pollina LE, Fontanini G, Casalone R, Berlingieri MT, Giannini R et al. Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. J Clin Endocrinol Metab 1997;82:4094-100.
49. Enomoto T, Sugawa H, Inoue D, Miyamoto M, Kosugi S, Takahashi T et al. Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines. Cancer 1990;65:1971-9.
50. Iwasa K. Noguchi M, Mori K, Ohta N, Miyazaki I, Nonomura A et al. Anaplastic thyroid carcinoma producing the granulocyte colony stimulating factor (G-CSF): Report of a case. Surg Today 1995;25:158-60.
51. Marube H, AkamizuT, Kubota A, Kusaka S. Anaplastic thyroid carcinoma with prominent cardiac metastasis, accompanied by a marked leukocytosis with a neutrophilia and high GM-CSF level in serum. Int Med 1992;31:1107-11.
52. Tennvall J, Lundell G, Hallquist A, Wahlberq P, Wallin G, Tibblin S. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma: report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 1994;74:1348-54.
53. Lip GY, Jaap AJ, McCruden DC. A presentation of anaplastic carcinoma of the thyroid with symptomatic intra-abdominal metastases. Br J Clin Pract 1992;46:143-4.
54. Kapp DS, LiVolsi VA, Sanders MM. Anaplastic carcinoma following well-differentiated thyroid cancer: Etiological considerations.Yale J Biol Med 1982;55:521-8.
55. Samaan NA, Ordonez NG. Uncommon types of thyroid cancer. Endocrinol Metab Clin North Am 1990;19:637-48.
56. Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic carcinoma in fine needle aspirates. Acta Cytol 1996;40:953-8. (Pubitemid 26322348)
57. Wolf BC, Sheahan K, DeCoste D, Variakojis D, Alpern HD, Haselow RE. Immunohistochemical analysis of small cell tumors of the thyroid gland: an Eastern Cooperative Oncology Group study. Hum Pathol 1992;23:1252-61.
58. Holting T, Moller P, Tschahargane C, Meybier H, Buhr H, Herfarth C. Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma. World J Surg 1990;14:291-5.
59. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78:826-9.
60. Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P et al. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab 2004;89:5823-7.
61. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E et al. Germ-line mutations of the RET pro-to-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
62. Poppe K, Lahoutte T, Everaert H, Bossuyt A, Velkeniers B. The utility of multimodality imaging in anaplastic thyroid carcinoma. Thyroid 2004;14:981-2. (Pubitemid 39612920)
63. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973-91. Cancer 1997;79:564-73.
64. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategies for anaplastic carcinoma of the thyroid. World J Surg 2001;25:617-22.
65. Pacheco-Ojeda L, Martinez A, Alvarez M. Anaplastic thyroid carcinoma in Ecuador: analysis of prognostic factors. Int Surg 2000;86:117-21.
66. Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N, Kubo A et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002;131:245-8.
67. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:1330-5.
68. Ciampi R, Vivaldi A, Romei C, Del Guerra A, Salvadori P, Cosci B et al. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. MoL Cell Endocrinol 2008;291:57-62.
69. 18F]2-deoxy-2-fluoro-D- glucose. J Nucl Med 1978;19:1154-61.
70. 18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer, J Clin Endocrinol Metab 2000;85:1107-13.
71. Feine U. Fluoro-18-deoxyglucose positron emission tomography in differentiated thyroid carcinoma. Eur J Endocrinol 1998;138:492-6.
72. Grunwald F, Schomburg A, Bender H, Hemm E, Menze C, Bultmann T et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312-9.
73. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797-804. (Pubitemid 29409664)
74. McDougall IR, Jadvar H, Segall G. PET scan in patients with suspected recurrent thyroid cancer [Abstract]. Thyroid 1998;8:1222.
75. Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2- deoxy-D-glucose Positron Emission Tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 2005;12:254-60. (Pubitemid 41552318)
76. Tezelman S, Clark OH. Current management of thyroid cancer. Adv Surg 1995;28:191-221.
77. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 1996;156:2165-72.
78. Levendag PC, De Porre PM, van Putten WL. Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 1993;26:125-8.
79. Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuja F et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996;18:36-41. (Pubitemid 26002035)
80. Simpson WJ. Anaplastic thyroid carcinoma: a new approach. Can J Surg 1980;23:25-7.
81. Wong CS, Can Dyk K, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1991;20:3-9.
82. Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination adriamycin and radiation therapy: a new approach. Cancer 1983;52:954-7.
83. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372-5.
84. Asakawa H, Kobayashi T, Komoike Y, Maruyama H, Nakano Y, Tamaki Y et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 1997;17:2757-62.
85. Pacini F, Viti P, Martino E. Treatment of refractory thyroid cancer with adriamycin. Drugs Exp Clin Res 1984;10:911-5.
86. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60.
87. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987;10:303-10.
88. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 1991;14:475-80.
89. Chemotherapy Committee, the Japanese Society of Thyroid Surgery. Intensive chemotherapy for anaplastic thyroid carcinoma: Combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte colony-stimulating factor support. Jpn J Clin Oncol 1995;25:203-7.
90. Auersperg M, Us-Krasovec M, Petric G, Poqacnik A, Besic N. Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma. Wien Klin Wochenschr 1990;102:267-70. (Pubitemid 20156794)
91. Biganzoli L, Gebbia V, Maiorino L, Caraci P, Iirillo A. Thyroid cancer: Different outcomes to chemotherapy according to tumour histology (Letter). Eur J Cancer 1995;31A:2423-4.
92. Heron DE, Karimpour S, Grigsby PW. Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am J Clin Oncol 2002;25:442-6.
93. Ribechini A, Bottici V, Chella A, Elisei R, Vitti P, Pinchera A et al. Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer. J Endocrinol Invest 2006;29:131-5.
94. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991;67:564-6.
95. Pierie JP, Muzikansky A, Gaz RD, Faguin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002;9:57-64.
96. Mitchell G, Huddart R, Harmer C. Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1999;50:33-8.
97. Wong CS, Van Dyk J, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1991;20:3-9.
98. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999;84:4043-9. (Pubitemid 30644192)
99. Weisman SM, Loree TR, Rigual NR, Hicks WL, Douglas WG, Anderson GR et al. Anaplastic transformation of thyroid cancer; review of clinical, pathologic and molecular evidence provides new insights into disease biology and future therapy. Head Neck 2003;25:662-70.
100. Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE et al. Effects of p53 expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab1998;83:2516-22.
101. Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H et al. Adenovirus mediated tumour suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 2000;85:4081-6.
102. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase II trial using ninety-six hour infusion. Thyroid 2000;7:587-94.
103. Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 2000;60:650-6.
104. Xu G, Pan J, Martin C, Yeung SC. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2001;86:1769-77.
105. Pan J, Xu G, Yeung SC. Cytochrome c release is upstream to activation of caspase-9, caspase-8 and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab 2001;86:4731-40.
106. Dowlati A, Robertson C, Cooney M, Petros WP, Stratford M, Jesberger J et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
107. Randal J. Antiangiogenesis drugs target specific cancers, mechanisms. J Natl Cancer Inst 2000;92:520-2. (Pubitemid 30212308)
108. Dziba JM, Marcinek R, Venkataraman GM, Robinson JA, Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumours. Thyroid 2002;12:1063-70. (Pubitemid 36114813)
109. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
110. Stenner F, Liewen H, Zweifel M, Weber A, Tchinda J, Bode B et al. Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci. 2008 Jun 20. [Epub ahead of print].
111. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K et at. Phase II Trial of Sorafenib in Advanced Thyroid Cancer. J Clin Oncol. 2008 Jun 9. [Epub ahead of print].
112. Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 1999;84:2449-57.
113. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. The sodium iodide symporter and its potential in cancer therapy. J Clin Endocrinol Metab 2001;86:3327-35.